Latest News

11 April 2018

Starpharma to present at OTCQX Virtual Investor Conference

Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that as part of its OTCQX investor communications, a pre-recorded presentation by Chief Executive Officer Dr Jackie Fairley will be broadcast at VirtualInvestorConferences.com on Thursday 12 April 2018 at 10:30am (US ET time).

Read more

14 March 2018

Starpharma on CommSec’s The Executive Series

Starpharma CEO Dr Jackie Fairley speaks with CommSec’s Tom Piotrowski about the Company’s performance since March 2017, its partnership with AstraZeneca and upcoming milestones.

To view the video, click here

8 March 2018

Starpharma CEO Dr Jackie Fairley on Channel 9’s The Today Show for International Women’s Day

As part of International Women’s Day, Starpharma CEO Dr Jackie Fairley appeared with the Federal Minister for Women Kelly O’Dwyer and Today Show presenter Georgie Gardiner to discuss women in the workforce and gender equality.

To view the video, click here.

26 February 2018

Starpharma Interim Report and Half-Year Financial Results

Starpharma today released its interim report and financial results for the half-year ended 31 December 2017.

Read more

In the media

14 March 2018

Starpharma on CommSec’s The Executive Series

Starpharma CEO Dr Jackie Fairley speaks with CommSec’s Tom Piotrowski about the Company’s performance since March 2017, its partnership with AstraZeneca and upcoming milestones.

To view the video, click here

8 March 2018

Starpharma CEO Dr Jackie Fairley on Channel 9’s The Today Show for International Women’s Day

As part of International Women’s Day, Starpharma CEO Dr Jackie Fairley appeared with the Federal Minister for Women Kelly O’Dwyer and Today Show presenter Georgie Gardiner to discuss women in the workforce and gender equality.

To view the video, click here.

31 January 2018

Starpharma announces DEP cabazitaxel Phase 1/2 Trial

Morningstar reported on Starpharma's announcement regarding the commencement of its phase 1/2 clinical trial for DEP cabazitaxel having received regulatory and ethics approvals. 

Go to article (external link)

23 January 2018

AstraZeneca plans to make better use of Australia’s innovation

The Australian highlighted Starpharma’s partnership with global pharmaceutical company AstraZeneca, noting the application of Starpharma’s DEP® technology platform helps make cancer drugs more effective, more patient-friendly and less toxic.
Go to the article (external link)

Shareholder Updates

19 February 2018

Shareholder Update February 2018

In this issue: 

>> New sites open for the DEP® docetaxel phase 2 trial

>> DEP® cabazitaxel phase 1 / 2 trial commences

>> VivaGel® BV NDA submission lodged under Fast Track program

>> VivaGel® BV approved by TGA

>> DEP® irinotecan progressing towards the clinic

>> AstraZeneca-Starpharma collaboration

>> Extensive global licensing negotiations for VivaGel® BV

>> Positive market research findings for VivaGel® BV 

>> Q2 Cashflow Report at 31 December 2017

>> OTCQX market recognition

>> Starpharma News & Events

>> Outlook

 Download: Shareholder Update February 2018 (pdf file, 1.5mb)

18 October 2017

Shareholder Update October 2017

In this issue: 

>> DEP® docetaxel achieves positive phase 1 results and commences phase 2

 >> AZ presents first DEP® candidate AZD0466 – a Bcl2/xL inhibitor

>>  Successful VivaGel® BV phase 3 results

>> Update on other internal DEP® candidates

>> Grant awarded to Starpharma-Monash

>> Starpharma and Peter Mac Cancer Centre awarded grant

>> FY17 Financial results; >$60M cash at 30 June

>> Annual Report and Annual General Meeting

>> Starpharma News & Events

 

Download: Shareholder Update October 2017 (pdf file, 1.3mb)

Sign up to receive news here

© Starpharma Holdings Limited 2017